Circulating Protein Fragments of Cartilage and Connective Tissue Degradation Are Diagnostic and Prognostic Markers of Rheumatoid Arthritis and Ankylosing Spondylitis

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Bay Jensen, Anne C ^a   Wichuk, Stephanie ^b   Byrjalsen, Inger ^a   Leeming, Diana J ^a   Morency, Nathalie ^b   Christiansen, Claus ^a   Karsdal, Morten A ^a   Maksymowych, Walter P ^b  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 2; COLLAGEN TYPE 3;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CARTILAGE DEGENERATION; COLLAGEN DEGRADATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RHEUMATOID ARTHRITIS; SOFT TISSUE INFLAMMATION;

ADULT; AGED; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CARTILAGE; CASE-CONTROL STUDIES; COLLAGEN TYPE II; COLLAGEN TYPE III; DECISION TREES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEOLYSIS; ROC CURVE; SPONDYLITIS, ANKYLOSING;

EID: 84872871447     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054504     Document Type: Article

References (31)

1. Lories RJ, Baeten DL, (2009) Differences in pathophysiology between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 27: S10-S14.
2. Goldring SR, (2003) Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 42: ii11-ii16.
3. Braun J, Pincus T, (2002) Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 20: S16-S22.
4. Tam LS, Gu J, Yu D, (2010) Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 6: 399-405.
5. Colbert RA, Deodhar AA, Fox D, Gravallese EM, Khan MA, et al. (2009) Entheses and bones in spondyloarthritis: 2008 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). J Rheumatol 36: 1527-1531.
6. Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, et al. (2009) Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 14: 181-202.
7. Segovia-Silvestre T, Bonnefond C, Sondergaard BC, Christensen ST, Karsdal MA, et al. (2011) Identification of the Calcitonin receptor in osteoarthritic chondrocytes. BMC Res Notes 4: 407.
8. Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, et al. (2005) In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 3: 553-580.
9. Garnero P, Desmarais S, Charni N, Percival MD, (2005) The CII fragments Helix-II and CTX-II reveal distinct enzymatic pathways of cartilage collagen degradation: diagnostic and therapeutic implications in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 52: P51.
10. de VK, (2010) Soluble and tissue biomarkers in ankylosing spondylitis. Best Pract Res Clin Rheumatol 24: 671-682.
11. Maksymowych WP, Landewe R, Conner-Spady B, Dougados M, Mielants H, et al. (2007) Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56: 1846-1853.
12. Bay-Jensen AC, Liu Q, Byrjalsen I, Li Y, Wang J, et al. (2011) Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM--increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem 44: 423-429.
13. Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, et al. (2010) A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem In press.
14. Bay-Jensen AC, Leeming DJ, Kleyer A, Veidal SS, Schett G, et al. (2011) Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol Int.
15. Veidal SS, Vassiliadis E, Barascuk N, Zhang C, Segovia-Silvestre T, et al. (2010) Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int 30: 1293-1304.
16. Vassiliadis E, Larsen DV, Clausen RE, Veidal SS, Barascuk N, et al. (2011) Measurement of CO3-610, a Potential Liver Biomarker Derived from Matrix Metalloproteinase-9 Degradation of Collagen Type III, in a Rat Model of Reversible Carbon-Tetrachloride-Induced Fibrosis. Biomark Insights 6: 49-58.
17. Vassiliadis E, Veidal SS, Simonsen H, Larsen DV, Vainer B, et al. (2011) Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis. Biomarkers.
18. van der LS, Valkenburg HA, Cats A, (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27: 361-368.
19. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, et al. (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21: 2286-2291.
20. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, et al. (2005) Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 64: 127-129.
21. Maksymowych WP, Landewe R, Tak PP, Ritchlin CJ, Ostergaard M, et al. (2009) Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol 36: 1785-1791.
22. Maksymowych WP, FitzGerald O, Wells GA, Gladman DD, Landewe R, et al. (2009) Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol 36: 1792-1799.
23. Ruof J, Stucki G, (1999) Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 26: 966-970.
24. Schett G, (2007) Joint remodelling in inflammatory disease. Ann Rheum Dis 66Suppl 3: iii42-iii44.
25. Schett G, Sieper J, (2009) Inflammation and repair mechanisms. Clin Exp Rheumatol 27: S33-S35.
26. Spoorenberg A, van der HD, de KE, Dougados M, de VK, et al. (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26: 980-984.
27. Lukas C, Braun J, van der HD, Hermann KG, Rudwaleit M, et al. (2007) Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J Rheumatol 34: 862-870.
28. Maksymowych WP, Dhillon SS, Park R, Salonen D, Inman RD, et al. (2007) Validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging spinal inflammation index: is it necessary to score the entire spine? Arthritis Rheum 57: 501-507.
29. Wanders AJ, Gorman JD, Davis JC, Landewe RB, van der Heijde DM, (2004) Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. Arthritis Rheum 51: 1-8.
30. de Vries MK, van E, I, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, et al. (2009) Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 61: 1484-1490.
31. Gelse K, Poschl E, Aigner T, (2003) Collagens--structure, function, and biosynthesis. Advanced Drug Delivery Reviews 55: 1531-1546.